Bioporto interview with CEO Tony Paré and CFO Niel A. Goldman about upcoming rights issue and status on NGAL.
Rights issue of DKK 59,4 mio. with pre-emptive rights. So far DKK 16,6 mio. or 28% has been subscribed by largest shareholders, management and entire board of directors. Subscription period starts the 6th. of June and last day 19th. of June. Trading in rights started the 1st. of June and last day of trading is the 15th. of June. Slides from this presentation and further details in danish, you will find at the Bioporto homepage under the menu "Investor Relations".
Listen to the interview here: https://www.inderes.dk/videos/bioporto-rights-issue
We will host a new event the 12th. of June with status on the rights issue. Both CEO Tony Paré and CFO Niel A. Goldman will participate. We will soon launch the link at https://hcandersencapital.dk/events/
Disclaimer:
HC Andersen Capital receives payment from Bioporto for a DigitalIR/Corporate Visibility agreement.
BioPorto
BioPorto is a Danish in-vitro diagnostics company with headquarters in Copenhagen, Denmark. The company was founded in 2000. BioPorto has one marketed product, the NGAL test, for early diagnosis of acute kidney injury (AKI), which is commercially available in Europe, Canada, Asia, and Israel. It has received breakthrough designation from the FDA for AKI in the pediatric indication, for which it is currently conducting data analysis following the completion of enrollment of patients for its Phase 3 study which will lead to an expected application to FDA. Future plans include further FDA submission for adult indication as well as other markets.
Read more on company page